首页 > 最新文献

Journal of Pharmaceutical Analysis最新文献

英文 中文
Hepatic protein phosphatase 1 regulatory subunit 3G alleviates obesity and liver steatosis by regulating the gut microbiota and bile acid metabolism 肝蛋白磷酸酶 1 调节亚基 3G 通过调节肠道微生物群和胆汁酸代谢缓解肥胖和肝脂肪变性
IF 8.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-11 DOI: 10.1016/j.jpha.2024.100976
Chu Zhang, Gui Wang, Xin Yin, Lingshan Gou, Mengyuan Guo, Feng Suo, Tao Zhuang, Zhenya Yuan, Yanan Liu, Maosheng Gu, Ruiqin Yao
Intestinal dysbiosis and disrupted bile acid (BA) homeostasis are associated with obesity, but the precise mechanisms remain insufficiently explored. Hepatic protein phosphatase 1 regulatory subunit 3G (PPP1R3G) plays a pivotal role in regulating glycolipid metabolism; nevertheless, its obesity-combatting potency remains unclear. In this study, a substantial reduction was observed in serum PPP1R3G levels in high-body mass index (BMI) and high-fat diet (HFD)-exposed mice, establishing a positive correlation between PPP1R3G and non-12α-hydroxylated (non-12-OH) BA content. Additionally, hepatocyte-specific overexpression of (PPP1R3G HOE) mitigated HFD-induced obesity as evidenced by reduced weight, fat mass, and an improved serum lipid profile; hepatic steatosis alleviation was confirmed by normalized liver enzymes and histology. PPP1R3G HOE considerably impacted systemic BA homeostasis, which notably increased the non-12-OH BAs ratio, particularly lithocholic acid (LCA). 16S ribosomal DNA (16S rDNA) sequencing assay indicated that PPP1R3G HOE reversed HFD-induced gut dysbiosis by reducing the / ratio and population, and elevating the relative abundance of , which exhibited a positive correlation with serum LCA levels. A fecal microbiome transplantation test confirmed that the anti-obesity effect of hepatic PPP1R3G was gut microbiota-dependent. Mechanistically, PPP1R3G HOE markedly suppressed hepatic cholesterol 7α-hydroxylase (CYP7A1) and sterol-12α-hydroxylase (CYP8B1), and concurrently upregulated oxysterol 7-α hydroxylase and Takeda G protein-coupled BA receptor 5 (TGR5) expression under HFD conditions. Furthermore, LCA administration significantly mitigated the HFD-induced obesity phenotype and elevated non-12-OH BA levels. These findings emphasize the significance of hepatic PPP1R3G in ameliorating diet-induced adiposity and hepatic steatosis through the gut microbiota-BA axis, which may serve as potential therapeutic targets for obesity-related disorders.
肠道菌群失调和胆汁酸(BA)平衡紊乱与肥胖有关,但其确切机制仍未得到充分探讨。肝脏蛋白磷酸酶 1 调节亚基 3G(PPP1R3G)在调节糖脂代谢中起着关键作用,但其对抗肥胖的功效仍不清楚。在这项研究中,观察到高体重指数(BMI)和高脂饮食(HFD)暴露小鼠血清中的 PPP1R3G 水平大幅降低,从而确立了 PPP1R3G 与非 12α- 羟基化(non-12-OH)BA 含量之间的正相关性。此外,肝细胞特异性过表达(PPP1R3G HOE)可减轻 HFD 诱导的肥胖,表现为体重和脂肪量减少,血清脂质状况改善;肝脏酶和组织学正常化证实肝脏脂肪变性减轻。PPP1R3G HOE极大地影响了全身BA的平衡,显著增加了非12-OH BAs的比例,尤其是石胆酸(LCA)。16S 核糖体 DNA(16S rDNA)测序分析表明,PPP1R3G HOE 通过降低非 12-OH-BAs的比例和种群数量,提高非 12-OH-BAs的相对丰度,逆转了 HFD 引起的肠道菌群失调,而非 12-OH-BAs的比例和种群数量与血清 LCA 水平呈正相关。粪便微生物组移植试验证实,肝脏 PPP1R3G 的抗肥胖作用是肠道微生物群依赖性的。从机理上讲,PPP1R3G HOE能显著抑制肝脏胆固醇7α-羟化酶(CYP7A1)和甾醇-12α-羟化酶(CYP8B1),并同时上调氧甾醇7-α羟化酶和武田G蛋白偶联BA受体5(TGR5)的表达。此外,服用 LCA 能明显减轻 HFD 诱导的肥胖表型和非 12-OH BA 水平的升高。这些发现强调了肝脏 PPP1R3G 在通过肠道微生物群-BA 轴改善饮食诱导的肥胖和肝脏脂肪变性中的重要作用,它可能成为肥胖相关疾病的潜在治疗靶点。
{"title":"Hepatic protein phosphatase 1 regulatory subunit 3G alleviates obesity and liver steatosis by regulating the gut microbiota and bile acid metabolism","authors":"Chu Zhang, Gui Wang, Xin Yin, Lingshan Gou, Mengyuan Guo, Feng Suo, Tao Zhuang, Zhenya Yuan, Yanan Liu, Maosheng Gu, Ruiqin Yao","doi":"10.1016/j.jpha.2024.100976","DOIUrl":"https://doi.org/10.1016/j.jpha.2024.100976","url":null,"abstract":"Intestinal dysbiosis and disrupted bile acid (BA) homeostasis are associated with obesity, but the precise mechanisms remain insufficiently explored. Hepatic protein phosphatase 1 regulatory subunit 3G (PPP1R3G) plays a pivotal role in regulating glycolipid metabolism; nevertheless, its obesity-combatting potency remains unclear. In this study, a substantial reduction was observed in serum PPP1R3G levels in high-body mass index (BMI) and high-fat diet (HFD)-exposed mice, establishing a positive correlation between PPP1R3G and non-12α-hydroxylated (non-12-OH) BA content. Additionally, hepatocyte-specific overexpression of (PPP1R3G HOE) mitigated HFD-induced obesity as evidenced by reduced weight, fat mass, and an improved serum lipid profile; hepatic steatosis alleviation was confirmed by normalized liver enzymes and histology. PPP1R3G HOE considerably impacted systemic BA homeostasis, which notably increased the non-12-OH BAs ratio, particularly lithocholic acid (LCA). 16S ribosomal DNA (16S rDNA) sequencing assay indicated that PPP1R3G HOE reversed HFD-induced gut dysbiosis by reducing the / ratio and population, and elevating the relative abundance of , which exhibited a positive correlation with serum LCA levels. A fecal microbiome transplantation test confirmed that the anti-obesity effect of hepatic PPP1R3G was gut microbiota-dependent. Mechanistically, PPP1R3G HOE markedly suppressed hepatic cholesterol 7α-hydroxylase (CYP7A1) and sterol-12α-hydroxylase (CYP8B1), and concurrently upregulated oxysterol 7-α hydroxylase and Takeda G protein-coupled BA receptor 5 (TGR5) expression under HFD conditions. Furthermore, LCA administration significantly mitigated the HFD-induced obesity phenotype and elevated non-12-OH BA levels. These findings emphasize the significance of hepatic PPP1R3G in ameliorating diet-induced adiposity and hepatic steatosis through the gut microbiota-BA axis, which may serve as potential therapeutic targets for obesity-related disorders.","PeriodicalId":16737,"journal":{"name":"Journal of Pharmaceutical Analysis","volume":"50 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142203885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction notice to “A DNA-based nanocarrier for efficient cancer therapy” [J. Pharm. Anal. 11 (2021) 330–339] 基于 DNA 的纳米载体用于高效癌症治疗》的撤稿通知 [J. Pharm. Anal. 11 (2021) 330-339]
IF 8.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-19 DOI: 10.1016/j.jpha.2024.100963
Muhammad Abbas, Mirza Muhammad Faran Ashraf Baig, Yaliang Zhang, Yu-Shun Yang, Songyu Wu, Yiqiao Hu, Zhong-Chang Wang, Hai-Liang Zhu
{"title":"Retraction notice to “A DNA-based nanocarrier for efficient cancer therapy” [J. Pharm. Anal. 11 (2021) 330–339]","authors":"Muhammad Abbas, Mirza Muhammad Faran Ashraf Baig, Yaliang Zhang, Yu-Shun Yang, Songyu Wu, Yiqiao Hu, Zhong-Chang Wang, Hai-Liang Zhu","doi":"10.1016/j.jpha.2024.100963","DOIUrl":"https://doi.org/10.1016/j.jpha.2024.100963","url":null,"abstract":"","PeriodicalId":16737,"journal":{"name":"Journal of Pharmaceutical Analysis","volume":"49 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140181988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mapping conformational changes on bispecific antigen-binding biotherapeutic by covalent labeling and mass spectrometry 通过共价标记和质谱法绘制双特异性抗原结合生物治疗剂的构象变化图
IF 8.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-16 DOI: 10.1016/j.jpha.2024.100966
Arnik Shah, Dipanwita Batabyal, Dayong Qiu, Weidong Cui, John Harrahy, Alexander R. Ivanov
Biotherapeutic’s higher order structure (HOS) is a critical determinant of its functional properties and conformational relevance. Here, we evaluated two covalent labeling methods: diethylpyrocarbonate (DEPC)-labeling and fast photooxidation of proteins (FPOP), in conjunction with mass spectrometry (MS), to investigate structural modifications for the new class of immuno-oncological therapy known as bispecific antigen-binding biotherapeutics (BABB). The evaluated techniques unveiled subtle structural changes occurring at the amino acid residue level within the antigen-binding domain under both native and thermal stress conditions, which cannot be detected by conventional biophysical techniques, e.g., near-ultraviolet circular dichroism (NUV-CD). The determined variations in labeling uptake under native and stress conditions, corroborated by binding assays, shed light on the binding effect, and highlighted the potential of covalent-labeling methods to effectively monitor conformational changes that ultimately influence the product quality. Our study provides a foundation for implementing the developed techniques in elucidating the inherent structural characteristics of novel therapeutics and their conformational stability.
生物治疗药物的高阶结构(HOS)是决定其功能特性和构象相关性的关键因素。在这里,我们评估了两种共价标记方法:二乙基吡咯碳酸酯(DEPC)标记法和蛋白质快速光氧化法(FPOP),并结合质谱法(MS)来研究被称为双特异性抗原结合生物疗法(BABB)的新型免疫肿瘤疗法的结构修饰。所评估的技术揭示了在原生和热应力条件下抗原结合结构域内氨基酸残基水平发生的微妙结构变化,而这些变化是传统生物物理技术(如近紫外光圆二色仪(NUV-CD))无法检测到的。在原生和应力条件下标记吸收的确定变化得到了结合试验的证实,揭示了结合效应,并突出了共价标记方法有效监测构象变化的潜力,而构象变化最终会影响产品质量。我们的研究为利用所开发的技术阐明新型疗法的固有结构特征及其构象稳定性奠定了基础。
{"title":"Mapping conformational changes on bispecific antigen-binding biotherapeutic by covalent labeling and mass spectrometry","authors":"Arnik Shah, Dipanwita Batabyal, Dayong Qiu, Weidong Cui, John Harrahy, Alexander R. Ivanov","doi":"10.1016/j.jpha.2024.100966","DOIUrl":"https://doi.org/10.1016/j.jpha.2024.100966","url":null,"abstract":"Biotherapeutic’s higher order structure (HOS) is a critical determinant of its functional properties and conformational relevance. Here, we evaluated two covalent labeling methods: diethylpyrocarbonate (DEPC)-labeling and fast photooxidation of proteins (FPOP), in conjunction with mass spectrometry (MS), to investigate structural modifications for the new class of immuno-oncological therapy known as bispecific antigen-binding biotherapeutics (BABB). The evaluated techniques unveiled subtle structural changes occurring at the amino acid residue level within the antigen-binding domain under both native and thermal stress conditions, which cannot be detected by conventional biophysical techniques, e.g., near-ultraviolet circular dichroism (NUV-CD). The determined variations in labeling uptake under native and stress conditions, corroborated by binding assays, shed light on the binding effect, and highlighted the potential of covalent-labeling methods to effectively monitor conformational changes that ultimately influence the product quality. Our study provides a foundation for implementing the developed techniques in elucidating the inherent structural characteristics of novel therapeutics and their conformational stability.","PeriodicalId":16737,"journal":{"name":"Journal of Pharmaceutical Analysis","volume":"25 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140181993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medcheck: a novel software for automatic de-formulation of traditional Chinese medicine (TCM) prescriptions by liquid chromatography-mass spectrometry Medcheck:利用液相色谱-质谱联用技术自动对传统中药(TCM)处方进行去配方的新型软件
IF 8.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-12 DOI: 10.1016/j.jpha.2024.02.012
Xiao-lan Li, Jian-qing Zhang, Yun Li, Xuan-jing Shen, Huan-ya Yang, Lin Yang, Meng Xu, Qi-rui Bi, Chang-liang Yao, De-an Guo
[Display omitted]
[显示省略]
{"title":"Medcheck: a novel software for automatic de-formulation of traditional Chinese medicine (TCM) prescriptions by liquid chromatography-mass spectrometry","authors":"Xiao-lan Li, Jian-qing Zhang, Yun Li, Xuan-jing Shen, Huan-ya Yang, Lin Yang, Meng Xu, Qi-rui Bi, Chang-liang Yao, De-an Guo","doi":"10.1016/j.jpha.2024.02.012","DOIUrl":"https://doi.org/10.1016/j.jpha.2024.02.012","url":null,"abstract":"[Display omitted]","PeriodicalId":16737,"journal":{"name":"Journal of Pharmaceutical Analysis","volume":"25 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140129410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
17β-Estradiol, through activating the G protein-coupled estrogen receptor, exacerbates the complication of benign prostate hyperplasia in type 2 diabetes mellitus patients by inducing prostate proliferation 17β-雌二醇通过激活G蛋白偶联雌激素受体,诱导前列腺增生,从而加剧2型糖尿病患者良性前列腺增生的并发症
IF 8.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-12 DOI: 10.1016/j.jpha.2024.03.003
Tingting Yang, Zhen Qiu, Jiaming Shen, Yutian He, Longxiang Yin, Li Chen, Jiayu Yuan, Junjie Liu, Tao Wang, Zhenzhou Jiang, Changjiang Ying, Sitong Qian, Jinfang Song, Xiaoxing Yin, Qian Lu
Benign prostate hyperplasia (BPH) is one of the major chronic complications of type 2 diabetes mellitus (T2DM), and sex steroid hormones are common risk factors for the occurrence of T2DM and BPH. The profiles of sex steroid hormones are simultaneously quantified by LC-MS/MS in the clinical serum of patients, including simple BPH patients, newly diagnosed T2DM patients, T2DM complicated with BPH patients and matched healthy individuals. The G protein-coupled estrogen receptor (GPER) inhibitor G15, GPER knockdown lentivirus, the YAP1 inhibitor verteporfin, YAP1 knockdown/overexpression lentivirus, targeted metabolomics analysis, and Co-IP assays are used to investigate the molecular mechanisms of the disrupted sex steroid hormones homeostasis in the pathological process of T2DM complicated with BPH. The homeostasis of sex steroid hormone is disrupted in the serum of patients, accompanying with the proliferated prostatic epithelial cells (PECs). The sex steroid hormone metabolic profiles of T2DM patients complicated with BPH have the greatest degrees of separation from those of healthy individuals. Elevated 17β-estradiol (E2) is the key contributor to the disrupted sex steroid hormone homeostasis, and is significantly positively related to the clinical characteristics of T2DM patients complicated with BPH. Activating GPER by E2 via Hippo-YAP1 signaling exacerbates high glucose (HG)-induced PECs proliferation through the formation of the YAP1-TEAD4 heterodimer. Knockdown or inhibition of GPER-mediated Hippo-YAP1 signaling suppresses PECs proliferation in HG and E2 co-treated BPH-1 cells. The anti-proliferative effects of verteporfin, an inhibitor of YAP1, are blocked by YAP1 overexpression in HG and E2 co-treated BPH-1 cells. Inactivating E2/GPER/Hippo/YAP1 signaling may be effective at delaying the progression of T2DM complicated with BPH by inhibiting PECs proliferation.
良性前列腺增生(BPH)是2型糖尿病(T2DM)的主要慢性并发症之一,而性激素是T2DM和BPH发生的共同危险因素。本研究采用 LC-MS/MS 方法同时定量检测了单纯良性前列腺增生症患者、新诊断的 T2DM 患者、T2DM 并发良性前列腺增生症患者和匹配的健康人等患者临床血清中的性类固醇激素谱。通过G蛋白偶联雌激素受体(GPER)抑制剂G15、GPER敲除慢病毒、YAP1抑制剂verteporfin、YAP1敲除/外表达慢病毒、靶向代谢组学分析和Co-IP检测,研究性类固醇激素平衡紊乱在T2DM并发良性前列腺增生病理过程中的分子机制。伴随着前列腺上皮细胞(PECs)的增殖,患者血清中的性类固醇激素平衡被打破。并发前列腺增生症的 T2DM 患者的性类固醇激素代谢谱与健康人的差异最大。17β-雌二醇(E2)升高是导致性类固醇激素平衡失调的关键因素,与并发良性前列腺增生症的 T2DM 患者的临床特征呈显著正相关。E2通过Hippo-YAP1信号激活GPER,会通过形成YAP1-TEAD4异二聚体加剧高糖(HG)诱导的PECs增殖。敲除或抑制 GPER 介导的 Hippo-YAP1 信号可抑制 HG 和 E2 联合处理的 BPH-1 细胞中 PECs 的增殖。在 HG 和 E2 联合处理的 BPH-1 细胞中,YAP1 抑制剂 verteporfin 的抗增殖作用被 YAP1 的过表达所阻断。E2/GPER/Hippo/YAP1信号的失活可通过抑制PECs增殖而有效延缓T2DM并发良性前列腺增生症的进展。
{"title":"17β-Estradiol, through activating the G protein-coupled estrogen receptor, exacerbates the complication of benign prostate hyperplasia in type 2 diabetes mellitus patients by inducing prostate proliferation","authors":"Tingting Yang, Zhen Qiu, Jiaming Shen, Yutian He, Longxiang Yin, Li Chen, Jiayu Yuan, Junjie Liu, Tao Wang, Zhenzhou Jiang, Changjiang Ying, Sitong Qian, Jinfang Song, Xiaoxing Yin, Qian Lu","doi":"10.1016/j.jpha.2024.03.003","DOIUrl":"https://doi.org/10.1016/j.jpha.2024.03.003","url":null,"abstract":"Benign prostate hyperplasia (BPH) is one of the major chronic complications of type 2 diabetes mellitus (T2DM), and sex steroid hormones are common risk factors for the occurrence of T2DM and BPH. The profiles of sex steroid hormones are simultaneously quantified by LC-MS/MS in the clinical serum of patients, including simple BPH patients, newly diagnosed T2DM patients, T2DM complicated with BPH patients and matched healthy individuals. The G protein-coupled estrogen receptor (GPER) inhibitor G15, GPER knockdown lentivirus, the YAP1 inhibitor verteporfin, YAP1 knockdown/overexpression lentivirus, targeted metabolomics analysis, and Co-IP assays are used to investigate the molecular mechanisms of the disrupted sex steroid hormones homeostasis in the pathological process of T2DM complicated with BPH. The homeostasis of sex steroid hormone is disrupted in the serum of patients, accompanying with the proliferated prostatic epithelial cells (PECs). The sex steroid hormone metabolic profiles of T2DM patients complicated with BPH have the greatest degrees of separation from those of healthy individuals. Elevated 17β-estradiol (E2) is the key contributor to the disrupted sex steroid hormone homeostasis, and is significantly positively related to the clinical characteristics of T2DM patients complicated with BPH. Activating GPER by E2 via Hippo-YAP1 signaling exacerbates high glucose (HG)-induced PECs proliferation through the formation of the YAP1-TEAD4 heterodimer. Knockdown or inhibition of GPER-mediated Hippo-YAP1 signaling suppresses PECs proliferation in HG and E2 co-treated BPH-1 cells. The anti-proliferative effects of verteporfin, an inhibitor of YAP1, are blocked by YAP1 overexpression in HG and E2 co-treated BPH-1 cells. Inactivating E2/GPER/Hippo/YAP1 signaling may be effective at delaying the progression of T2DM complicated with BPH by inhibiting PECs proliferation.","PeriodicalId":16737,"journal":{"name":"Journal of Pharmaceutical Analysis","volume":"5 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140129418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progress and application of intelligent nanomedicine in urinary system tumors 智能纳米医学在泌尿系统肿瘤中的进展与应用
IF 8.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-12 DOI: 10.1016/j.jpha.2024.100964
Yingming Xiao, Lei Zhong, Jinpeng Liu, Li Chen, Yi Wu, Ge Li
Urinary system tumors include malignancies of the bladder, kidney, and prostate, and present considerable challenges in diagnosis and treatment. The conventional therapeutic approaches against urinary tumors are limited by the lack of targeted drug delivery and significant adverse effects, thereby necessitating novel solutions. Intelligent nanomedicine has emerged as a promising therapeutic alternative for cancer in recent years, and uses nanoscale materials to overcome the inherent biological barriers of tumors, and enhance diagnostic and therapeutic accuracy. In this review, we have explored the recent advances and applications of intelligent nanomedicine for the diagnosis, imaging, and treatment of urinary tumors. The principles of nanomedicine design pertaining to drug encapsulation, targeting and controlled release have been discussed, with emphasis on the strategies for overcoming renal clearance and tumor heterogeneity. Furthermore, the therapeutic applications of intelligent nanomedicine, its advantages over traditional chemotherapy, and the challenges currently facing clinical translation of nanomedicine, such as safety, regulation and scalability, have also been reviewed. Finally, we have assessed the potential of intelligent nanomedicine in the management of urinary system tumors, emphasizing emerging trends such as personalized nanomedicine and combination therapies. This comprehensive review underscores the substantial contributions of nanomedicine to the field of oncology and offers a promising outlook for more effective and precise treatment strategies for urinary system tumors.
泌尿系统肿瘤包括膀胱、肾脏和前列腺的恶性肿瘤,给诊断和治疗带来了巨大挑战。传统的泌尿系统肿瘤治疗方法受限于缺乏靶向给药和显著的不良反应,因此需要新的解决方案。近年来,智能纳米医学作为一种有前景的癌症治疗方法出现,它利用纳米级材料克服肿瘤固有的生物障碍,提高诊断和治疗的准确性。在这篇综述中,我们探讨了智能纳米医学在泌尿系统肿瘤诊断、成像和治疗方面的最新进展和应用。我们讨论了与药物封装、靶向和控释有关的纳米药物设计原理,重点是克服肾清除和肿瘤异质性的策略。此外,还综述了智能纳米药物的治疗应用、与传统化疗相比的优势,以及纳米药物临床转化目前面临的挑战,如安全性、监管和可扩展性。最后,我们评估了智能纳米医学在治疗泌尿系统肿瘤方面的潜力,强调了个性化纳米医学和联合疗法等新兴趋势。这篇全面的综述强调了纳米医学对肿瘤学领域的巨大贡献,并为泌尿系统肿瘤更有效、更精确的治疗策略提供了美好的前景。
{"title":"Progress and application of intelligent nanomedicine in urinary system tumors","authors":"Yingming Xiao, Lei Zhong, Jinpeng Liu, Li Chen, Yi Wu, Ge Li","doi":"10.1016/j.jpha.2024.100964","DOIUrl":"https://doi.org/10.1016/j.jpha.2024.100964","url":null,"abstract":"Urinary system tumors include malignancies of the bladder, kidney, and prostate, and present considerable challenges in diagnosis and treatment. The conventional therapeutic approaches against urinary tumors are limited by the lack of targeted drug delivery and significant adverse effects, thereby necessitating novel solutions. Intelligent nanomedicine has emerged as a promising therapeutic alternative for cancer in recent years, and uses nanoscale materials to overcome the inherent biological barriers of tumors, and enhance diagnostic and therapeutic accuracy. In this review, we have explored the recent advances and applications of intelligent nanomedicine for the diagnosis, imaging, and treatment of urinary tumors. The principles of nanomedicine design pertaining to drug encapsulation, targeting and controlled release have been discussed, with emphasis on the strategies for overcoming renal clearance and tumor heterogeneity. Furthermore, the therapeutic applications of intelligent nanomedicine, its advantages over traditional chemotherapy, and the challenges currently facing clinical translation of nanomedicine, such as safety, regulation and scalability, have also been reviewed. Finally, we have assessed the potential of intelligent nanomedicine in the management of urinary system tumors, emphasizing emerging trends such as personalized nanomedicine and combination therapies. This comprehensive review underscores the substantial contributions of nanomedicine to the field of oncology and offers a promising outlook for more effective and precise treatment strategies for urinary system tumors.","PeriodicalId":16737,"journal":{"name":"Journal of Pharmaceutical Analysis","volume":"24 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140129737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiotracer labelled thymohydroquinyl gallate capped gold nanoparticles as theranostic radiopharmaceutical for targeted antineoplastic and bioimaging 放射性示踪剂标记的胸腺氢醌没食子酸酯封端金纳米粒子作为治疗放射性药物用于靶向抗肿瘤和生物成像
IF 8.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-12 DOI: 10.1016/j.jpha.2024.100965
Munaza Batool, Batool Fatima, Dilshad Hussain, Rubaida Mahmood, Muhammad Imran, Saeed Akhter, Muhammad Saqib Khan, Saadat Majeed, Muhammad Najam-ul-Haq
Thymoquinone (Tq) and gallic acid (GA) are known for counter-tumorigenic characteristics. GA inhibits cancer cell proliferation by interfering with many apoptotic signaling pathways, producing more reactive oxygen species (ROS), focusing on the cell cycle, and suppressing the expression of oncogenes and matrix metalloproteinases (MMPs). In this study, thymoquinone (after reducing to thymohydroquinone) and gallic acid are esterified to form thymohydroquinyl gallate (a prodrug). Thymohydroquinyl gallate (THQG) possesses enhanced antineoplastic efficacy and targeted delivery potential. The chemical and spectroscopic analysis confirms ester synthesis. Gold nanoparticles (AuNPs) are employed as nanocarriers due to their physicochemical and optical characteristics, biocompatibility, and low toxicity. As an efficient drug transporter, gold nanoparticles (AuNPs) shield conjugated drugs from enzymatic digestion. The prodrug acts as a reducing agent for Au metal atoms and is loaded onto it after reduction. The nano drug is radiolabeled with Tc and I to monitor the drug biodistribution in animals using a gamma camera and single-photon emission computerized tomography (SPECT). I is an antineoplastic that helps enhance the drug's efficiency. Chromatographic results reveal promising radiolabeling percentages. drug release shows sustained release at pH⁓5.8. 3−[4,5−dimethylthiazol−2−yl]−2,5 diphenyl tetrazolium bromide (MTT) cytotoxicity assay reveals drug potency on CAL 27 and MCF 7 cell lines.
胸腺醌(Tq)和没食子酸(GA)具有抗肿瘤特性。GA通过干扰多种凋亡信号通路、产生更多活性氧(ROS)、关注细胞周期以及抑制癌基因和基质金属蛋白酶(MMPs)的表达来抑制癌细胞增殖。在这项研究中,胸腺醌(还原成胸腺氢醌后)和没食子酸酯化形成胸腺氢醌没食子酸酯(原药)。胸腺氢醌没食子酸酯(THQG)具有更强的抗肿瘤功效和靶向递送潜力。化学和光谱分析证实了酯的合成。金纳米粒子(AuNPs)因其物理化学和光学特性、生物相容性和低毒性而被用作纳米载体。作为一种高效的药物运输工具,金纳米粒子(AuNPs)可以保护共轭药物不被酶消化。原药作为金金属原子的还原剂,在还原后被载入其上。纳米药物用锝和碘进行放射性标记,利用伽马相机和单光子发射计算机断层扫描(SPECT)监测药物在动物体内的生物分布。I 是一种抗肿瘤物质,有助于提高药物的效率。色谱结果显示放射性标记的百分比很有希望。药物释放显示在 pH 值⁓5.8 时可持续释放。3-[4,5-二甲基噻唑-2-基]-2,5-二苯基溴化四氮唑(MTT)细胞毒性试验显示了药物对 CAL 27 和 MCF 7 细胞株的效力。
{"title":"Radiotracer labelled thymohydroquinyl gallate capped gold nanoparticles as theranostic radiopharmaceutical for targeted antineoplastic and bioimaging","authors":"Munaza Batool, Batool Fatima, Dilshad Hussain, Rubaida Mahmood, Muhammad Imran, Saeed Akhter, Muhammad Saqib Khan, Saadat Majeed, Muhammad Najam-ul-Haq","doi":"10.1016/j.jpha.2024.100965","DOIUrl":"https://doi.org/10.1016/j.jpha.2024.100965","url":null,"abstract":"Thymoquinone (Tq) and gallic acid (GA) are known for counter-tumorigenic characteristics. GA inhibits cancer cell proliferation by interfering with many apoptotic signaling pathways, producing more reactive oxygen species (ROS), focusing on the cell cycle, and suppressing the expression of oncogenes and matrix metalloproteinases (MMPs). In this study, thymoquinone (after reducing to thymohydroquinone) and gallic acid are esterified to form thymohydroquinyl gallate (a prodrug). Thymohydroquinyl gallate (THQG) possesses enhanced antineoplastic efficacy and targeted delivery potential. The chemical and spectroscopic analysis confirms ester synthesis. Gold nanoparticles (AuNPs) are employed as nanocarriers due to their physicochemical and optical characteristics, biocompatibility, and low toxicity. As an efficient drug transporter, gold nanoparticles (AuNPs) shield conjugated drugs from enzymatic digestion. The prodrug acts as a reducing agent for Au metal atoms and is loaded onto it after reduction. The nano drug is radiolabeled with Tc and I to monitor the drug biodistribution in animals using a gamma camera and single-photon emission computerized tomography (SPECT). I is an antineoplastic that helps enhance the drug's efficiency. Chromatographic results reveal promising radiolabeling percentages. drug release shows sustained release at pH⁓5.8. 3−[4,5−dimethylthiazol−2−yl]−2,5 diphenyl tetrazolium bromide (MTT) cytotoxicity assay reveals drug potency on CAL 27 and MCF 7 cell lines.","PeriodicalId":16737,"journal":{"name":"Journal of Pharmaceutical Analysis","volume":"26 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140129419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms and therapeutic targets of ferroptosis: Implications for nanomedicine design 铁中毒的机制和治疗靶点:对纳米药物设计的启示
IF 8.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-08 DOI: 10.1016/j.jpha.2024.03.001
Meihong Zhang, Mengqin Guo, Yue Gao, Chuanbin Wu, Xin Pan, Zhengwei Huang
Ferroptosis is a nonapoptotic form of cell death and differs considerably from the well-known forms of cell death in terms of cell morphology, genetics, and biochemistry. The three primary pathways for cell ferroptosis are system Xc/glutathione peroxidase 4, lipid metabolism, and ferric metabolism. Since the discovery of ferroptosis, mounting evidence has revealed its critical regulatory role in several diseases, especially as a novel potential target for cancer therapy, thereby attracting increasing attention in the fields of tumor biology and anti-tumor therapy. Accordingly, broad prospects exist for identifying ferroptosis as a potential therapeutic target. In this review, we aimed to systematically summarize the activation and defense mechanisms of ferroptosis, highlight the therapeutic targets, and discuss the design of nanomedicines for ferroptosis regulation. In addition, we opted to present the advantages and disadvantages of current ferroptosis research and provide an optimistic vision of future directions in related fields. Overall, we aim to provide new ideas for further ferroptosis research and inspire new strategies for disease diagnosis and treatment.
铁凋亡是一种非凋亡性细胞死亡形式,在细胞形态、遗传学和生物化学方面与众所周知的细胞死亡形式有很大不同。细胞铁凋亡的三个主要途径是 Xc 系统/谷胱甘肽过氧化物酶 4、脂质代谢和铁代谢。自发现铁变态反应以来,越来越多的证据揭示了它在多种疾病中的关键调控作用,尤其是作为癌症治疗的潜在新靶点,从而引起了肿瘤生物学和抗肿瘤治疗领域越来越多的关注。因此,将铁蛋白变性确定为潜在治疗靶点具有广阔的前景。在这篇综述中,我们旨在系统地总结铁突变的激活和防御机制,突出治疗靶点,并讨论调控铁突变的纳米药物的设计。此外,我们还介绍了当前铁突变研究的优缺点,并对相关领域的未来发展方向提出了乐观的展望。总之,我们的目标是为进一步的铁蛋白沉积研究提供新思路,并为疾病诊断和治疗提供新策略。
{"title":"Mechanisms and therapeutic targets of ferroptosis: Implications for nanomedicine design","authors":"Meihong Zhang, Mengqin Guo, Yue Gao, Chuanbin Wu, Xin Pan, Zhengwei Huang","doi":"10.1016/j.jpha.2024.03.001","DOIUrl":"https://doi.org/10.1016/j.jpha.2024.03.001","url":null,"abstract":"Ferroptosis is a nonapoptotic form of cell death and differs considerably from the well-known forms of cell death in terms of cell morphology, genetics, and biochemistry. The three primary pathways for cell ferroptosis are system Xc/glutathione peroxidase 4, lipid metabolism, and ferric metabolism. Since the discovery of ferroptosis, mounting evidence has revealed its critical regulatory role in several diseases, especially as a novel potential target for cancer therapy, thereby attracting increasing attention in the fields of tumor biology and anti-tumor therapy. Accordingly, broad prospects exist for identifying ferroptosis as a potential therapeutic target. In this review, we aimed to systematically summarize the activation and defense mechanisms of ferroptosis, highlight the therapeutic targets, and discuss the design of nanomedicines for ferroptosis regulation. In addition, we opted to present the advantages and disadvantages of current ferroptosis research and provide an optimistic vision of future directions in related fields. Overall, we aim to provide new ideas for further ferroptosis research and inspire new strategies for disease diagnosis and treatment.","PeriodicalId":16737,"journal":{"name":"Journal of Pharmaceutical Analysis","volume":"2010 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140129330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
β-elemene promotes miR-127-3p maturation, induces NSCLCs autophagy, and enhances macrophage M1 polarization through exosomal communication β-榄香烯通过外泌体通讯促进 miR-127-3p 成熟、诱导 NSCLC 自噬并增强巨噬细胞 M1 极化
IF 8.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-08 DOI: 10.1016/j.jpha.2024.03.002
Xiahui Wu, Jie Wu, Tingting Dai, Qiangcheng Wang, Shengjie Cai, Xuehan Wei, Jing Chen, Ziyu Jiang
β-elemene has been observed to exert inhibitory effects on a multitude of tumors, primarily through multiple pathways such as the inhibition of cancer cell proliferation and the induction of apoptosis. The present study is designed to elucidate the role and underlying mechanisms of β-elemene in the therapeutic intervention of non-small cell lung cancer (NSCLC). Both in vitro and in vivo experimental models corroborate the inhibitory potency of β-elemene on NSCLCs. Our findings indicate that β-elemene facilitates the maturation of miR-127-3p by inhibiting CBX8. Functioning as an upstream regulator of MAPK4, miR-127-3p deactivates the Akt/mTOR/p70S6K pathway by targeting MAPK4, thereby inducing autophagy in NSCLCs. Additionally, β-elemene augments the packaging of miR-127-3p into exosomes via SYNCRIP. Exosomal miR-127-3p further stimulates M1 polarization of macrophages by suppressing ZC3H4. Taken together, the detailed understanding of the mechanisms through which β-elemene induces autophagy in NSCLCs and facilitates M1 polarization of macrophages provides compelling scientific evidence supporting its potential utility in NSCLC treatment.
据观察,β-榄香烯主要通过抑制癌细胞增殖和诱导细胞凋亡等多种途径对多种肿瘤产生抑制作用。本研究旨在阐明β-榄香烯在非小细胞肺癌(NSCLC)治疗干预中的作用和内在机制。体外和体内实验模型都证实了β-榄香烯对非小细胞肺癌的抑制作用。我们的研究结果表明,β-榄香烯通过抑制 CBX8 促进了 miR-127-3p 的成熟。作为 MAPK4 的上游调节因子,miR-127-3p 通过靶向 MAPK4 使 Akt/mTOR/p70S6K 通路失活,从而诱导 NSCLC 的自噬。此外,β-榄香烯还能通过 SYNCRIP 将 miR-127-3p 包入外泌体。外泌体 miR-127-3p 通过抑制 ZC3H4 进一步刺激巨噬细胞的 M1 极化。综上所述,通过详细了解β-榄香烯诱导NSCLC自噬和促进巨噬细胞M1极化的机制,为β-榄香烯在NSCLC治疗中的潜在应用提供了令人信服的科学证据。
{"title":"β-elemene promotes miR-127-3p maturation, induces NSCLCs autophagy, and enhances macrophage M1 polarization through exosomal communication","authors":"Xiahui Wu, Jie Wu, Tingting Dai, Qiangcheng Wang, Shengjie Cai, Xuehan Wei, Jing Chen, Ziyu Jiang","doi":"10.1016/j.jpha.2024.03.002","DOIUrl":"https://doi.org/10.1016/j.jpha.2024.03.002","url":null,"abstract":"β-elemene has been observed to exert inhibitory effects on a multitude of tumors, primarily through multiple pathways such as the inhibition of cancer cell proliferation and the induction of apoptosis. The present study is designed to elucidate the role and underlying mechanisms of β-elemene in the therapeutic intervention of non-small cell lung cancer (NSCLC). Both in vitro and in vivo experimental models corroborate the inhibitory potency of β-elemene on NSCLCs. Our findings indicate that β-elemene facilitates the maturation of miR-127-3p by inhibiting CBX8. Functioning as an upstream regulator of MAPK4, miR-127-3p deactivates the Akt/mTOR/p70S6K pathway by targeting MAPK4, thereby inducing autophagy in NSCLCs. Additionally, β-elemene augments the packaging of miR-127-3p into exosomes via SYNCRIP. Exosomal miR-127-3p further stimulates M1 polarization of macrophages by suppressing ZC3H4. Taken together, the detailed understanding of the mechanisms through which β-elemene induces autophagy in NSCLCs and facilitates M1 polarization of macrophages provides compelling scientific evidence supporting its potential utility in NSCLC treatment.","PeriodicalId":16737,"journal":{"name":"Journal of Pharmaceutical Analysis","volume":"23 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140129457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Trends and Impact of Localized Surface Plasmon Resonance (LSPR) and Surface-Enhanced Raman Spectroscopy (SERS) in Modern Analysis 局部表面等离子体共振 (LSPR) 和表面增强拉曼光谱 (SERS) 在现代分析中的最新趋势和影响
IF 8.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-02-28 DOI: 10.1016/j.jpha.2024.02.013
Bibhu Prasad Nanda, Priyanka Rani, Priyanka Paul, Ganti Subrahmanya S, Rohit Bhatia
An optical biosensor is a specialized analytical device that utilizes the principles of optics and light bimolecular processes. Localized surface plasmon resonance (LSPR) is a phenomenon in the realm of nanophotonics that arises when metallic nanoparticles (NPs) or nanostructures interact with incident light. On the other hand, surface-enhanced Raman spectroscopy (SERS) is an influential analytical technique rooted in Raman scattering, wherein it amplifies the Raman signals of molecules when they are situated near specific and specially designed nanostructures. A detailed exploration of the recent ground-breaking developments in optical biosensors employing LSPR and SERS technologies has been exhaustively discussed along with their underlying principle and the working mechanism. A biosensor chip has been created, featuring a high-density deposition of gold nanoparticles under varying ligand concentration and reaction duration on the substrate. An ordinary description, along with a visual illustration, has been thoroughly provided for concepts such as a sensogram, refractive index shift, surface plasmon resonance (SPR), and the evanescent field, Rayleigh scattering, Raman scattering as well as the electromagnetic enhancement & chemical enhancement. LSPR and SERS both have their advantages and disadvantages but widely used SERS has some advantages over LSPR like chemical specificity, high sensitivity, multiplexing, and versatility in different fields. This review confirms and elucidates the significance of different disease biomarker identification. LSPR, and SERS both play a vital role in the detection of various types of cancer like cervical cancer, ovarian cancer, endometrial cancer, prostate cancer, colorectal cancer, and brain tumors. This proposed optical biosensor provides potential application for early diagnosis and monitoring of viral disease, bacterial infectious diseases, fungal diseases, diabetes, and cardiac disease biosensing. LSPR and SERS provide a new direction for environmental monitoring, food safety, refining of impurities from water samples, and detection of lead. The understanding of these biosensors is still limited and challenging.
光学生物传感器是一种利用光学原理和光双分子过程的专用分析设备。局部表面等离子体共振(LSPR)是纳米光子学领域的一种现象,当金属纳米粒子(NPs)或纳米结构与入射光相互作用时就会产生这种现象。另一方面,表面增强拉曼光谱(SERS)是一种根植于拉曼散射的有影响力的分析技术,当分子位于特定和特殊设计的纳米结构附近时,它能放大分子的拉曼信号。本文详细探讨了采用 LSPR 和 SERS 技术的光学生物传感器的最新突破性发展及其基本原理和工作机制。我们制作了一个生物传感器芯片,其特点是在不同配体浓度和反应持续时间的情况下,在基底上高密度沉积金纳米粒子。对感应图、折射率偏移、表面等离子体共振(SPR)、蒸发场、瑞利散射、拉曼散射以及电磁增强和化学增强等概念进行了详尽的描述和形象的说明。LSPR 和 SERS 都有各自的优缺点,但广泛使用的 SERS 与 LSPR 相比具有一些优势,如化学特异性、高灵敏度、复用性和在不同领域的通用性。本综述证实并阐明了不同疾病生物标记物鉴定的重要性。LSPR 和 SERS 在检测宫颈癌、卵巢癌、子宫内膜癌、前列腺癌、结直肠癌和脑肿瘤等各种癌症方面都发挥着重要作用。这种拟议的光学生物传感器可用于病毒性疾病、细菌性传染病、真菌性疾病、糖尿病和心脏病生物传感的早期诊断和监测。LSPR 和 SERS 为环境监测、食品安全、提炼水样中的杂质和检测铅提供了新的方向。人们对这些生物传感器的了解仍然有限,而且具有挑战性。
{"title":"Recent Trends and Impact of Localized Surface Plasmon Resonance (LSPR) and Surface-Enhanced Raman Spectroscopy (SERS) in Modern Analysis","authors":"Bibhu Prasad Nanda, Priyanka Rani, Priyanka Paul, Ganti Subrahmanya S, Rohit Bhatia","doi":"10.1016/j.jpha.2024.02.013","DOIUrl":"https://doi.org/10.1016/j.jpha.2024.02.013","url":null,"abstract":"An optical biosensor is a specialized analytical device that utilizes the principles of optics and light bimolecular processes. Localized surface plasmon resonance (LSPR) is a phenomenon in the realm of nanophotonics that arises when metallic nanoparticles (NPs) or nanostructures interact with incident light. On the other hand, surface-enhanced Raman spectroscopy (SERS) is an influential analytical technique rooted in Raman scattering, wherein it amplifies the Raman signals of molecules when they are situated near specific and specially designed nanostructures. A detailed exploration of the recent ground-breaking developments in optical biosensors employing LSPR and SERS technologies has been exhaustively discussed along with their underlying principle and the working mechanism. A biosensor chip has been created, featuring a high-density deposition of gold nanoparticles under varying ligand concentration and reaction duration on the substrate. An ordinary description, along with a visual illustration, has been thoroughly provided for concepts such as a sensogram, refractive index shift, surface plasmon resonance (SPR), and the evanescent field, Rayleigh scattering, Raman scattering as well as the electromagnetic enhancement & chemical enhancement. LSPR and SERS both have their advantages and disadvantages but widely used SERS has some advantages over LSPR like chemical specificity, high sensitivity, multiplexing, and versatility in different fields. This review confirms and elucidates the significance of different disease biomarker identification. LSPR, and SERS both play a vital role in the detection of various types of cancer like cervical cancer, ovarian cancer, endometrial cancer, prostate cancer, colorectal cancer, and brain tumors. This proposed optical biosensor provides potential application for early diagnosis and monitoring of viral disease, bacterial infectious diseases, fungal diseases, diabetes, and cardiac disease biosensing. LSPR and SERS provide a new direction for environmental monitoring, food safety, refining of impurities from water samples, and detection of lead. The understanding of these biosensors is still limited and challenging.","PeriodicalId":16737,"journal":{"name":"Journal of Pharmaceutical Analysis","volume":"4 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140009894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pharmaceutical Analysis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1